• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    • Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Secukinumab versus adalimumab head-to-head comparison in biologic-naive patients with active psoriatic arthritis through 52-weeks (exceed): a randomised, double-blind, phase-3B study

    Author(s)
    Mcinnes, I
    Behrens, F
    Mease, PJ
    Kavanaugh, A
    Ritchlin, CT
    Nash, P
    Gratacos-Masmitja, J
    Goupille, P
    Korotaeva, T
    Gottlieb, AB
    Martin, R
    Ding, K
    Pellet, P
    Mpofu, S
    Pricop, L
    Griffith University Author(s)
    Nash, Peter
    Year published
    2020
    Metadata
    Show full item record
    Abstract
    Background: Secukinumab (SEC), an interleukin-17A inhibitor, has demonstrated improvements on multiple domains of psoriatic arthritis (PsA).1 Adalimumab (ADA), a TNF inhibitor, is widely used as a first–line biologic in PsA. Objectives: To report efficacy and safety outcomes from the head-to-head EXCEED trial (NCT02745080) that compares SEC vs. ADA as first–line biologic monotherapy through 52-weeks (wks), with a musculoskeletal primary endpoint in pts with active PsA. Methods: Head-to-head, phase-3b, randomised, double-blind trial: biologic naïve active PsA pts were randomised to receive SEC 300mg subcutaneous at baseline, ...
    View more >
    Background: Secukinumab (SEC), an interleukin-17A inhibitor, has demonstrated improvements on multiple domains of psoriatic arthritis (PsA).1 Adalimumab (ADA), a TNF inhibitor, is widely used as a first–line biologic in PsA. Objectives: To report efficacy and safety outcomes from the head-to-head EXCEED trial (NCT02745080) that compares SEC vs. ADA as first–line biologic monotherapy through 52-weeks (wks), with a musculoskeletal primary endpoint in pts with active PsA. Methods: Head-to-head, phase-3b, randomised, double-blind trial: biologic naïve active PsA pts were randomised to receive SEC 300mg subcutaneous at baseline, Wk1-4, and then every 4wks (q4w) until Wk48 or ADA 40mg subcutaneous at baseline and then q2w until Wk50. The primary endpoint was superiority of SEC vs. ADA on ACR20 response at Wk52. Binary and continuous variables were analysed using logistic-regression model and MMRM, respectively. Safety analysis included patients who received ≥1 dose of study-drug. Results: 853 pts were randomised to receive SEC (n=426) or ADA (n=427). Baseline demographics and disease characteristics were comparable between treatment-groups except higher proportion of female pts and pts without enthesitis in the SEC group. ACR20 response at Wk52 for SEC vs. ADA were 67·4% vs. 61·5%, respectively (p=0·0719) (Figure). Higher clinical responses were observed with SEC vs. ADA for a range of musculoskeletal, skin, and higher-hurdle outcomes (Table). A higher retention rate was observed for SEC (85.7%) vs. ADA (76.3%). Safety profiles of SEC and ADA were consistent with previous reports.2,3 Conclusion: Results suggest that SEC is at least as efficacious as ADA on musculoskeletal endpoints whilst providing higher responses on skin endpoints, and is associated with a higher retention rate. No new safety signals were reported.
    View less >
    Conference Title
    Annals of the Rheumatic Diseases
    Volume
    79
    Issue
    Suppl 1
    Publisher URI
    https://ard.bmj.com/content/79/Suppl_1/142
    Subject
    Clinical sciences
    Immunology
    Science & Technology
    Life Sciences & Biomedicine
    Rheumatology
    Publication URI
    http://hdl.handle.net/10072/399397
    Collection
    • Conference outputs

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E
    • TEQSA: PRV12076

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander